Bone strength depends on the amount of bone, typically expressed as bone mineral density (BMD), determined by dual-energy X-ray absorptiometry (DXA), and on bone quality. Bone quality is a multifactorial entity including bone structural and material compositional properties. The purpose of the present study was to examine whether bone material composition properties at actively-forming trabecular bone surfaces in health are dependent on subject age, and to contrast them with postmenopausal osteoporosis patients. To achieve this, we analyzed by Raman microspectroscopy iliac crest biopsy samples from healthy subjects aged 1.5 to 45.7 years, paired biopsy samples from females before and immediately after menopause aged 46.7 to 53.6 years, and biopsy samples from placebo-treated postmenopausal osteoporotic patients aged 66 to 84 years. The monitored parameters were as follows: the mineral/matrix ratio; the mineral maturity/crystallinity (MMC); nanoporosity; the glycosaminoglycan (GAG) content; the lipid content; and the pyridinoline (Pyd) content. The results indicate that these bone quality parameters in healthy, activelyforming trabecular bone surfaces are dependent on subject age at constant tissue age, suggesting that with advancing age the kinetics of maturation (either accumulation, or posttranslational modifications, or both) change. For most parameters, the extrapolation of models fitted to the individual age dependence of bone in healthy individuals was in rough agreement with their values in postmenopausal osteoporotic patients, except for MMC, lipid, and Pyd content. Among these three, Pyd content showed the greatest deviation between healthy aging and disease, highlighting its potential to be used as a discriminating factor.
Introduction

B
one strength depends on the amount of bone, typically expressed as bone mineral density (BMD), determined by dual-energy X-ray absorptiometry (DXA), and on quality. (1) Between the two, by far the most widely used metric is BMD, in order to establish and/or predict bone fracture risk. On the other hand, it is well established nowadays that BMD does not fully account for bone fracture risk. In cases in which discrepancy exists between estimated (based on BMD) and actual (fracture incidence) bone mechanical properties, bone quality is thought to be responsible. (1) Bone quality is a multifactorial entity including bone structural and material compositional properties.
(1-4) Both BMD and bone quality are influenced by bone turnover rates. (5, 6) Bone quality is also dependent on other factors such as homocysteine (which has been proposed as a fracture risk contributor). Moreover, the material compositional properties have been shown to significantly vary as a function of both subject and tissue age, (2, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) and correlate with bone's mechanical properties in both animal models and humans, (8, 11, 14, 16, 17) though tissue age was determined on general anatomical morphological criteria (eg, distance from Haversian canal in osteons) rather than more robust, histomorphometric criteria, and most of these studies focused on cortical bone.
The purpose of the present study was to expand on these previous findings and describe bone composition as a function of subject age at well-defined tissue ages in actively-forming trabecular bone surfaces (evidenced by the presence of fluorescent double labels) in iliac crest biopsy samples from healthy female donors aged 1.5 to 53.6 years, (7, 18, 19) and women diagnosed with postmenopausal osteoporosis aged 66 to 84 years, (20) by combining the previously published data and complementing them with new data. The study was motivated by two aims: (1) examine the dependence of bone compositional properties at actively-forming trabecular bone surfaces on subject age in a set of biopsy samples from healthy female subjects spanning 1 year of age to immediately following menopause, and establish regression models describing the variation of these bone properties in healthy aging; and (2) examine these parameters in iliac crest biopsy samples from placebo-receiving (calcium and vitamin D) postmenopausal osteoporosis patients to test whether "unique" changes occur in disease compared to healthy aging (based on regression modeling). Because in the present study we focused exclusively on actively-forming trabecular bone surfaces (based on the presence of double fluorescent labels), bone turnover (the ratio of bone formation and resorption) is not expected to be a confounding factor.
Materials and Methods
Human biopsy samples
Data from previously published studies were included in the present study. The following groups were considered:
Children and young adults
Iliac crest biopsy samples from healthy female children and young adults (C-YA) (mean age AE SD ¼ 13.35 AE 4.61 years; range, 1.5 to 20.9 years; n ¼ 32). These biopsies were acquired during surgery for various conditions requiring corrective surgery. The bone specimens were collected on day 4 or 5 after dual fluorescent labeling taken orally during two 2-day periods separated by a 10-day free interval. All subjects were ambulatory, had normal renal function (assessed by serum creatinine measurements), and had no evidence of any metabolic bone disease. None of the included subjects was either immobilized prior to surgery or received medications known to affect bone metabolism. (7, 21) Iliac crest biopsy samples were collected at least 5 days after dual labeling taken orally during two 2-day periods separated by a 10-day free interval.
Adults
Iliac crest biopsy samples from healthy adult females (AD) (mean age AE SD ¼ 37.3 AE 8.2 years; range, 20 to 48 years; n ¼ 36). (18) Women in this group had normal aBMD by DXA (T-score ! -1 or Z-score ! -1) and no history of adult low-trauma fractures. Premenopausal status was considered as regular menses off hormonal contraception and early follicular phase follicle stimulating hormone (FSH) levels <20 mIU/mL. Exclusion criteria were as follows: amenorrhea lasting 6 months or longer after menarche, fewer than eight menses/year, and a delivery or lactation in the last year. All participants had a detailed history, physical evaluation, and biochemical evaluation to exclude secondary causes of osteoporosis. Women with serum 25-hydroxyvitamin D (25-OH-D) levels below 10 ng/mL were excluded. Because vitamin D deficiency and insufficiency are common in healthy adults and commercial assays are variable, women with screening 25-OH-D levels between 10 and 20 ng/mL were eligible if their serum parathyroid hormone (PTH) was normal (10 to 65 pg/mL). (22) Iliac crest biopsy samples were collected at least 5 days after dual labeling taken orally during two 3-day periods separated by a 12-day free interval.
Healthy premenopausal women
Iliac crest biopsy samples from healthy women right before menopause (PreM) (mean age AE SD ¼ 49.4 AE 1.9 years; range, 47 to 53 years; n ¼ 9). (19) Inclusion criteria were an age of 46 years or older and a history of menses during the prior 2 years, even if somewhat irregular, as well as serum levels of E2 >50 pg/mL and FSH <25 mIU/mL on samples obtained between the 17th and 25th day of the menstrual cycle. Details on the inclusion/exclusion criteria have been previously published. (23) Iliac crest biopsy samples were collected at least 5 days after dual labeling taken orally during two 3-day periods separated by a 14-day free interval.
Healthy postmenopausal women
Iliac crest biopsy samples from the same healthy women as in PreM, 1 year after menopause (PostM) (mean age AE SD ¼ 54.6 AE 2.2 years; range, 49 to 55 years; n ¼ 9). (19, 23) Iliac crest biopsy samples were collected at least 5 days after dual labeling taken orally during two 3-day periods separated by a 14-day free interval.
Postmenopausal osteoporosis patients
Iliac crest biopsy samples from women who were diagnosed with postmenopausal osteoporosis and who received placebo for 3 years (PostM-OP) (mean age AE SD ¼ 71.8 AE 4.8 years; range, 65 to 84 years; n ¼ 66). (20) Iliac crest biopsy samples were collected at least 5 days after dual labeling taken orally during two 3-day periods separated by a 14-day free interval.
Raman analysis
Instrumental and spectral acquisition details have been published elsewhere. (7, (18) (19) (20) The variables considered in the present study are as follows:
1. The mineral/organic matrix ratio was expressed as the ratio of the integrated areas of the v 2 PO 4 (410-460 cm
À1
) to the amide III (1215-1300 cm À1 ) Raman bands. (24) This ratio, unlike BMD, accounts for both the amount of mineral and organic matrix present in the volume analyzed. It correlates with ash-weight measurements, (25) and has been shown in the rat animal model to correlate better with the bending stiffness and failure moment of the humerus compared to BMD. (26) 2. The mineral maturity/crystallinity (MMC) of the bone mineral apatite crystallites was approximated from the inverse of the full-width at half-height (FWHH) of the v 1 PO 4 (930-980 cm À1 ) band. This bone quality metric describes the chemical composition of the mineral crystallites (maturity), and by extrapolation their crystallinity (size and shape). (2, 4, 27) 3. Nanoporosity was approximated by the ratio of the integrated areas of the spectral slice 494 to 509 cm -1
(poly(methyl methacrylate) [PMMA] ) to amide III band. (19) The Raman signal comes from a voxel of $1 mm
3
, and the ratio is expected to be zero if there is no penetration of PMMA into this voxel of material. The more porosity there is, the more PMMA can penetrate and the larger this ratio will be. We call it nanoporosity, because the pores containing PMMA must be smaller than the voxel size, which is at submicron level (hence "nano"). 4. The relative glycosaminoglycans (GAG) content was calculated from the ratio of the integrated areas of the CH 3 (1365-1390 cm
À1
) band representative of GAG, (28) to the amide III (1215-1300 cm À1 ) band. In Raman spectroscopy, the spectral signature of proteoglycans is due to GAG chains. In bone, chondroitin 4-sulfate constitutes about 90% of the total GAG content, and the predominant proteoglycans are biglycan and decorin. (29) Proteoglycans have been shown to act as negative modulators of mineralization, bone turnover, and also to be present in microporous and nanoporous spaces such as osteocyte lacunae and the canalicular network. (30) (31) (32) (33) (34) 5. The relative lipid content was expressed as the ratio of the integrated area of the lipid band $1298 cm
/integrated area of amide III; (7, 19) lipids have been reported to be biomineralization promoters/nucleators. (35, 36) 6. The relative pyridinoline content was calculated from the ratio of the Raman intensity at 1660 cm
/the integrated area of the amide I band ($1620-1700 cm ). (7, 19) Pyd is a mature, nonreducible, trivalent collagen crosslink, abundant in mineralizing type I collagen. (37, 38) Anatomical area selection criteria All the analyzed biopsy samples contained tetracycline fluorescent double labels in the trabecular bone compartment (Fig. 1A) .
For each sample, three trabeculae were analyzed at three distinct tissue areas corresponding to different tissue ages: between the second label and the mineralizing front (TA1), between the two labels (TA2), and right behind (3 mm) the first label (TA3). In each of these regions three measurements were obtained, for a total of nine measurements per subject per anatomical area. For each, the average of these nine values, representative of every age-specific tissue region, was treated as a single statistical unit. A typical Raman spectrum with the bands of interest labeled is shown in Fig. 1B .
Statistical analysis
Subject age group results are presented as mean and SD at each specific tissue. Healthy subject groups (C-YA, AD, PreM, and PostM) were compared by two-way ANOVA followed by Tukey's multiple comparisons test. The two factors were subject group age and tissue age. Two-way ANOVA was also used to compare the PostM and PostM-OP groups with diagnosis and tissue age as the two factors. In all instances, significance was assigned to p < 0.05. Regression analyses was performed in two ways: (1) considering only the individual healthy data, and (2) considering all the individual subject data (including PostM-OP). The type of model (linear, Gaussian, second-order or third-order polynomial) was chosen according to the highest achievable r 2 values. For each parameter, the resulting regression models (based on the two different data sets considered) were compared against each other using the extra sum-of-squares F test to determine whether there was any statistical evidence that the two different data sets (healthy only versus healthy and PostM-OP subjects) differ from each other.
Results
The mean values AE SD for the monitored parameters in the various subject groups and tissue ages analyzed in the present study are shown in Table 1 . Results of the two-way ANOVA analyses are shown in Table 2 (healthy aging) and Table 3 (health versus disease; PostM versus PostM-OP), whereas the Tukey's multiple comparisons test results for the four healthy subject age groups are listed in Table 4 . The results of the regression modeling analyses and the statistical comparison depending on whether the PostM-OP individual values were included in the model or not, are shown in Table 5 .
In healthy aging, all monitored parameters were significantly dependent on both subject age group and tissue age ( Table 2) . When the PostM and PostM-OP subject groups were compared, all monitored parameters were significantly dependent on diagnosis and tissue age, with the exception of nanoporosity, which was dependent on tissue age only, and lipid content, which was dependent on diagnosis exclusively (Table 3) .
The mineral/matrix ratio increased as a function of tissue age in all healthy age groups (Table 1) . When the healthy individual patient data were considered, this ratio decreased (in a linear manner as determined by regression analysis) as a function of subject age at all three tissue ages considered ( Fig. 2A-C) , with the rate of decline increasing with increasing tissue age (slopes of -0.001326 AE 0.0004115, p ¼ 0.0018; -0.002737 AE 0.001131, p < 0.0177; and -0.004734 AE 0.001220, p ¼ 0.0002, for TA1, TA2, and TA3 tissue ages, respectively). The subject groups were not different at the TA1 tissue age (Table 4) . Notably, the PostM and PostM-OP groups had similar values, with the exception of TA3, in which the PostM-OP group had lower values (Table 4) . Differences between the healthy subject groups were evident at the two older tissue ages analyzed (Table 4) . Finally, there was no dependency of the generated regression model on whether just the healthy individual values, or all (including the PostM-OP) were considered, at any of the three tissue ages analyzed in the present study (Table 5) .
MMC, based on individual healthy subject data, was unaltered at TA1 (p ¼ 0.1630), whereas it decreased at TA2 (slope ¼ -6.982 Â 10 -5 AE 2.581 Â 10
, p < 0.0001) ( Fig. 2D-F ). At the youngest tissue age (TA1), all healthy subject groups had similar MMC, whereas this metric was significantly increased in the PostM-OP compared to PostM group (Table 4) . Between the two fluorescent double labels, significant differences existed between subject groups, unlike the oldest tissue age considered ( Table 4 ). The dependency on individual healthy subject age was a linear one ( Fig. 2D -F, Table 5 ). Statistical analyses of the regression model revealed that significant differences existed depending on whether the PostM-OP individual values were included in the considerations or not, at all three tissue ages investigated (Table 5) . For each subject group, the top value is for the TA1, the middle for the TA2, and the bottom for the TA3 tissue age analyzed. FWHH ¼ full width at half height of the v 1 PO 4 Raman band; PMMA ¼ poly(methyl methacrylate); C-YA ¼ healthy female children and young adults; AD ¼ healthy adult females; PreM ¼ healthy women right before menopause; PostM ¼ PreM women 1 year after menopause; PostM-OP ¼ women who were diagnosed with postmenopausal osteoporosis and who received placebo for 3 years; TA1 ¼ tissue area between the second label and the mineralizing front; TA2 ¼ tissue area between the two labels; TA3 ¼ tissue area right behind the first label. The p values are listed. MMC ¼ mineral maturity/crystallinity.
The PostM and PostM-OP groups had similar nanoporosity values (Tables 1 and 4 ). When subject groups were compared, some differences in nanoporosity among the groups at the TA1 and TA2 tissue ages were evident, unlike the older tissue age analyzed (TA3; Table 4 ). Nanoporosity (Table 5 , Fig. 2G -I) variation in health was best described by a second-degree regression model, reaching a minimum in the AD group at all three tissue ages considered. There was no dependency of the generated regression model on whether just the healthy individual values, or all (including the PostM-OP) were considered, at any of the three tissue ages analyzed in the present study (Table 5) .
Although differences in GAG content among the healthy subject groups were evident at all three tissue ages analyzed, the PostM and PostM-OP groups had similar values except at TA3 (Tables 1 and 4) , whereas the PostM-OP group had significantly lower content (Table 1 ). The relative GAG content exhibited a Gaussian relationship to healthy individual subject age at all three tissue ages analyzed (Table 5 , Fig. 3A-C ; r 2 ¼ 0.587, 0.509, and 0.458, for the TA1, TA2, and TA3 tissue ages, respectively), with the maximum values evident in the AD subject group. There were no significant differences in the generated regression model depending on whether the PostM-OP individual values were included in the considerations or not ( Table 5) .
The relative lipid content maximum values were evident in the AD subject group (Table 1 ). Significant differences at the TA1 tissue age considered between the healthy subject groups were evident with the exception of PreM and PostM groups (Table 4) , whereas the PostM-OP group had significantly lower values compared to the PostM group (Tables 1 and 4) . The relative lipid content also exhibited a Gaussian relationship to healthy individual subject age at all three tissue ages analyzed (Table 5 , Fig. 3D-F ; r 2 ¼ 0.502, 0.500, and 0.585, for the TA1, TA2, and TA3 tissue ages, respectively). Statistical analyses of the regression model revealed that significant differences exist depending on whether the PostM-OP individual values were included in the considerations or not, at two of the three tissue ages investigated (TA1 and TA3; Table 5 ).
In health, the highest relative Pyd content was evident in the C-YA and AD groups, whereas it was significantly reduced in the PreM and PostM groups (Fig. 3G-I ) at all three tissue ages analyzed. Significant differences were evident at the youngest (TA1) tissue analyzed except between the PreM and PostM groups (Tables 1 and 4) , whereas the PostM-OP had significantly elevated TA1 TA2 TA3   TA1   TA2   TA3   TA1   TA2   TA3   TA1   TA2  TA3 TA1 TA2 TA3 TA1 TA2 For each parameter, the left value is for comparisons at the youngest tissue age (TA1) considered, the middle value is for the label (TA2), and the right value is for the older tissue age (TA3 (Tables 1 and 4 ) in all three tissue ages considered. At all three tissue ages considered, the relationship between the relative Pyd content and healthy individual subject age was also best represented by a Gaussian function (Table 5 , Fig. 3G-I ; r 2 ¼ 0.402, 0.456, and 0.476, for the TA1, TA2, and TA3 tissue ages, respectively). Comparison of the two different ways of regression modeling analyses reveals that inclusion of the PostM-OP individual values renders the Gaussian model non-feasible (Table 5) ; instead, a third-order polynomial is required to fit all the individual values (data not shown).
Analysis of covariance (ANCOVA) analyses (data not shown) indicated that the slopes were significantly different among the three tissue ages considered for the mineral/organic matrix ratio and MMC.
Discussion
Overall bone mineral and organic matrix properties are dependent on factors such as health, subject age (mainly due to variable bone turnover rates), and tissue age. In the present study we used Raman microspectroscopic analyses to examine bone material composition characteristics as well as their maturation kinetics at actively-forming trabecular bone surfaces in a set of human iliac crest biopsy samples from healthy female individuals. Because specific tissue ages were compared, bone turnover was not a confounding factor. We also performed the same type of analyses in a cohort of human iliac crest biopsy samples from subjects diagnosed with postmenopausal osteoporosis to examine whether differences between healthy aging and disease exist. In an effort to compare healthy aging versus PostM-OP, and because we did not have access to iliac crest biopsies from healthy female individuals who were age-matched with PostM-OP individuals, regression model analyses was performed on the individual values of the healthy patients, followed by testing whether the model changes upon inclusion of the PostM-OP values.
All monitored parameters were significantly dependent on tissue age in both health and PostM-OP, further accentuating the need to account for it when microscopic techniques are employed.
Based on subject age group data, the results indicated that composition was significantly dependent not only on tissue age, but also on subject age group when similar tissue ages were considered, suggesting that the function/work of the osteoblast and/or the accumulation/posttranslational modification kinetics is dependent on subject age in health. Comparison of healthy PostM versus PostM-OP subjects at similar tissue ages revealed differences between the two groups in all monitored bone quality indices except nanoporosity. On the other hand, comparison of healthy aging versus PostM-OP based on individual subject data regression modeling analyses suggests that these differences cannot be discriminately assigned to either anticipated advanced aging (because the PostM-OP subjects were older than the oldest healthy individual) or disease, with the exceptions of MMC, lipid, and PYD content, the last showing the greatest promise to serve as a discriminant factor. The r 2 values are listed. Bold values are statistically significant. Modeling was performed in two different ways: for healthy subjects only, and for all subjects (including PostM-OP). For the pyridinoline content parameter, when all data was treated as a continuum, it was impossible to apply a Gaussian model (instead a 3rd degree polynomial was required to fit the data). NF means not feasible to fit with a Gaussian model; instead, a third-degree polynomial provides the best fit.
TA ¼ tissue age; PostM-OP ¼ women who were diagnosed with postmenopausal osteoporosis and who received placebo for 3 years; TA1 ¼ tissue area between the second label and the mineralizing front; TA2 ¼ tissue area between the two labels; TA3 ¼ tissue area right behind the first label; MMC ¼ mineral maturity/crystallinity; NF ¼ not feasible.
Data based on subject age group
When subject age group data were considered, a decline in the mineral/matrix ratio with progressing age is evident. An interesting observation emerged once the PostM-OP group was compared to the healthy PostM age group (Table 4) . This ratio is similar between the two groups at TA1 and TA2 (Table 4) , whereas it is significantly lower at TA3 in the PostM-OP group (Tables 1 and 4 ). This lack of differences at TA1 and TA2 coupled with the significant decline at TA3 would then suggest the bone matrix initially formed by the osteoblasts is the same in both groups, whereas the kinetics of accumulation are altered in disease.
Significant differences in MMC between the subject-age groups at specific tissue ages were more evident in the area between the two fluorescent labels ( Table 4 ). The reason for this is unclear, although the data would be in agreement with a published report showing that regions labeled with fluorochrome have lower mean mineral thickness and degree of mineral alignment. (39) MMC was significantly higher in the PostM-OP compared to PostM group at the younger (TA1 and TA 2) tissue ages, in agreement with published reports. (40, 41) Indeed, elevated values may contribute to the bone fragility evident in postmenopausal osteoporosis, because altered MMC has previously been associated with fragile bone, and theoretical considerations suggest that larger crystallites may be detrimental to the mechanical properties of the bone composite. (1, (40) (41) (42) (43) (44) Minor differences were evident in nanoporosity between healthy age groups, most notably the AD group having significantly lower values compared to C-YA at TA1 and TA2, and PostM at TA1 (Tables 1 and 4) . Interestingly, the lowest values were in the AD age group, around which time the peak bone mass is usually encountered. (45) GAG content was significantly higher in the AD group compared to the other healthy groups. The significant decline in the PreM and PostM groups compared to AD would be in agreement with data on skin decorin, showing that in advanced Fig. 2 . Maturation kinetics at three distinct tissue ages (TA1, TA, TA3) of newly formed mineralized matrix, estimated by the mineral to matrix ratio (A-C), the MMC (D-F), and the nanoporosity (G-I), as a function of the age of normal or untreated osteoporotic individuals. The mineral to matrix ratio shows a clear decreasing trend with the age of the individual that is getting stronger with more advanced tissue maturation. MMC slightly decreases at TA2 and TA3 as a function of individual healthy subject age. Nanoporosity decreases rapidly during tissue maturation and the lowest values are encountered in the AD group. The colors indicate the origin of the biopsy samples from a variety of clinical studies, including healthy children and adolescents (open circles), (7) healthy adults (red), (18) healthy premenopausal (black) and postmenopausal (yellow) women, (19) as well as postmenopausal osteoporotic patients (green). (20) MMC ¼ mineral maturity/crystallinity.
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aging, the size of the GAG chains is greatly reduced while the average size of the decorin protein remains unaltered. (46) Thus, changes in the spectroscopically determined GAG content may be due to either changes in proteoglycan content, or altered posttranslational modifications, or altered microporosity and nanoporosity (proteoglycans are abundant in the canalicular network (34) ), or any combination of the three. In disease (PostM-OP), the GAG content was significantly lower than in health (PostM) at TA3. This result would be consistent with the previously mentioned altered posttranslational modifications in advanced aging (the average subject age of the PostM-OP group is $20 years older than that of the PostM one).
In health, the highest lipid content was evident in the AD group (Tables 1 and 4 ), in agreement with their suggested biological role (35, 36) as biomineralization nucleators, because this is the subject group in which the highest bone mass is usually encountered.
(45) The lipid content was significantly lower in the PostM-OP compared to the PostM group (Tables 1 and 4) , consistent with the lower mineral/organic matrix ratio in the same group.
The greatest Pyd content values in healthy age groups were evident in the C-YA and AD groups (Tables 1 and 4) , followed by a significant decrease in the PreM and PostM groups. The fact that the highest values occurred in the C-YA and AD groups would be consistent with biochemical data showing that the maximum concentration is reached by 10 to 15 years of age, (38) although it should be kept in mind that in the present study only the younger tissue ages were considered, unlike the biochemical analyses. Although the experimental design of the present study does not permit the determination of the underlying cause of the significant decrease in PreM and PostM groups, one plausible reason could be decelerated conversion of divalent to trivalent cross-links, or modulation of Pyd content by estrogen. (47) Interestingly, when PostM-OP was compared to PostM, the Pyd content was significantly higher in the former, at all three tissue ages considered. This finding would be in general Fig. 3 . Composition of the organic matrix in newly forming bone with different maturity stages (TA1, TA2, TA3) and as a function of the age of the individual. Content in glycosaminoglycans (A-C), lipid (D-F), and pyridinoline cross-links (G-I) were evaluated. First, there is no obvious change in composition with the maturation of the matrix (from youngest outside the second tetracycline label to the oldest inside the first label). There are some remarkable effects related to the age of the individuals: lipid and GAG are higher for the ages close to peak bone mass (red symbols in A-F) whereas pyridinoline values are particularly low for perimenopausal women (black and yellow dots in G-I). All three parameters exhibit a Gaussian distribution in health as a function of individual subject age. Symbol colors are as defined in Fig. 2. agreement with the higher Pyd/divalent collagen cross-link ratio at actively-forming trabecular bone surfaces in both postmenopausal and in idiopathic osteoporosis. (48) (49) (50) Data based on individual subject age and regression model analysis
Because the PostM and PostM-OP subject groups were not agematched, the differences between healthy age groups and PostM-OP discussed thus far, could not be categorically assigned as differences between healthy aging and disease. We therefore considered the individual healthy subject data to build a regression model for healthy aging. Following this, we examined whether or not addition of the PostM-OP individual data left the model unaltered (in which case disease effects may not be discriminated from healthy advancing age ones).
Based on individual healthy subject data, the bone matrix mineral deposition (calculated as the mineral/organic matrix ratio) decelerated with advancing subject age, at all three tissue ages considered ( Fig. 2A-C) , in general agreement with a recently published study. (15) The individual healthy subject data were best described by a linear regression model, and the rate of decline increased with tissue age. Interestingly, when healthy subject and PostM-OP data were treated as a continuum, the best regression model remained the linear one, the resulting r 2 values at TA2 and TA3 increased, whereas statistical comparison of the two regression lines (without and with the PostM-OP data included) revealed no significant differences ( Table 5 ), suggesting that this metric is not suitable to discriminate between healthy advancing aging and postmenopausal osteoporosis.
Healthy individual subject data showed that the MMC variation as a function of age was also best represented by a linear regression model at all three tissue ages considered (Table 5 , Fig. 2D-F) . Although treating healthy and PostM-OP individual data as a continuum resulted in a linear regression model as well, the r 2 values at TA1 and TA3 were considerably altered and the slopes of the two generated regression lines were significantly different ( Table 5 ), suggesting that this bone quality metric may be useful in discriminating between healthy aging and postmenopausal osteoporosis, especially when determined at TA1. Nanoporosity generally decreased with maturation and was by far highest in freshly deposited matrix of young individuals (Fig. 2G) . In health, its dependence on age was best described by a second-degree polynomial regression model. Inclusion of PostM-OP subject values did not greatly impact the calculated r 2 coefficients (Table 5) , and statistical comparison of the two regression models revealed no statistical differences, suggesting that this bone quality index may not be discriminant enough to distinguish between health and PostM-OP.
GAG content exhibited a Gaussian distribution as a function of subject age with the highest values evident in the AD group (Table 5 , Fig. 3A-C) , in agreement with published data showing that iduronate content in biglycan and decorin increases with subject age. (51) The subsequent significant decline in the PreM and PostM groups would be in agreement with data on skin decorin showing that in advanced aging, the size of the GAG chains is greatly reduced whereas the average size of the decorin protein remains unaltered. (46) Inclusion of the PostM-OP individual data in the regression analyses considerations improved the calculated r 2 values (Table 5 ), but there were no statistical differences between the two regression models, suggesting that this metric may not be used to discriminate between healthy aging and PostM-OP.
Lipid content in healthy subjects also exhibited a Gaussian distribution as a function of subject age, with the highest values evident in the AD group (Table 5 , Fig. 3D-F) . Inclusion of the PostM-OP individual data in the regression analyses considerations improved the calculated r 2 values, and resulted in statistical differences between the two models, suggesting that this bone quality index may serve as a discriminating factor between healthy advancing aging and PostM-OP.
Consideration of the individual healthy subject Pyd content values showed that it also exhibited a Gaussian distribution as a function of subject age (Table 5 , Fig. 3G-I) . On the other hand, it was impossible to include the PostM-OP data without changing the regression model from Gaussian to third-order polynomial (data not shown) at all three tissue ages, suggesting that this bone quality metric is a strong candidate to serve as a discriminant parameter between healthy aging and PostM-OP. Its potential of serving as a differentiating marker between health and disease is also highlighted in published studies involving untreated osteoporosis patients (50) as well as female idiopathic osteoporosis patients; in these studies it was able to discriminate between the patients who sustained fragility fractures and the ones who did not, regardless of BMD values. (18, 48, 50, 52) The limitations of the present study include the low subject numbers in the PreM and PostM groups (due to the difficulty in obtaining tetracycline labeled biopsy samples from healthy patients), and the absence of a healthy control group that would be closer (age-wise) to the PostM-OP group (due to the scarcity of tetracycline double-labeled iliac crest biopsy specimens from healthy female subjects in their mid-seventies). The subject group that was used for PostM-OP was the placebo-receiving group from the previously analyzed Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) clinical trial, (20) indicating that although the patients were diagnosed as postmenopausal osteoporotic, they were receiving calcium and vitamin D, which may have interfered with the results. The biopsy samples used in the present study originated from different clinical studies, thus differences in the specimen preparation procedures cannot be excluded (although the protocols were nominally similar). Fluorescent labeling is known to influence mineral characteristics within the double label, (39) and the fluorescent labeling protocol was not identical for all groups examined in the present study. Although data were not collected at the fluorescent lines themselves (but sufficiently away), we cannot fully exclude some influence on MMC. On the other hand, because all biopsy samples used were double labeled, it is likely that any artifacts are consistent among all specimens analyzed, thus not affecting between-group comparisons. Finally, the considerations put forth are applicable only to actively-forming trabecular bone surfaces, and may not necessarily be reflective of forming surfaces in cortical bone. As a matter of fact, we have previously shown that the tissue maturation kinetics are different at bone forming surfaces between the two different bone compartments, (20) albeit in biopsy samples from postmenopausal osteoporosis patients.
In summary, the results of the present study showed that the monitored parameters of bone quality were dependent on both tissue and subject age, notwithstanding the fact that locations of similar tissue age were compared among the different subject age groups. The fact that differences existed between the various healthy age groups even at constant tissue age suggests that the osteoblast function/work and/or rate of accumulation/ posttranslational modifications are dependent on subject age. Comparison of healthy aging versus PostM-OP based on individual subject data showed that MMC, lipid, and Pyd content may serve as differentiating indices between healthy aging and PostM-OP. Between these three, the most discriminant property between healthy aging and disease was the relative Pyd content, because inclusion of PostM-OP values resulted in a change of the regression model built on healthy individual subject data. Enzymatic collagen cross-links are known to contribute to bone strength, affecting both the stiffness and the toughness. (53) (54) (55) Interestingly, in cases where predicted bone strength and actual fracture incidence considerations were divergent, collagen enzymatic cross-links, to date, always correlated with the latter. (18, 48, 50, 52, (56) (57) (58) (59) One possible explanation for this is that although stiffness depends on modulus, bone toughness depends on interfaces, (60) and in the actively-forming trabecular bone areas examined in the present study a major interface close to TA3 is present, namely the cement line. (61) This hypothesis is further supported by results obtained in antler bone, which infer that extrinsic/microscale collagen-based characteristics and hypermineralized seams/ "zones" may play an important role in imparting the remarkable bone toughness seen in antler. (62) It is conceivable then to hypothesize that the increased relative Pyd content in these anatomical areas reduces bone toughness by increasing the local stiffness. This would also account for micro-anatomical area confined (restricted only at actively-forming bone surfaces) changes in the enzymatic collagen cross-links influencing the strength of whole bone, even in the absence of concomitant changes in either bone mineral quantity or quality. (57, 59) Thus, enzymatic collagen cross-links at actively-forming bone surfaces show great potential as a discriminating determinant of healthy aging as opposed to postmenopausal osteoporosis. Finally, the data generated on the healthy subjects may be used as reference in future studies of diseases such as osteogenesis imperfecta and premenopausal idiopathic osteoporosis.
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